A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

Exclusion Criteria

• •Participation in any other study involving investigational drug(s) during the study and within 4 weeks prior to study entry
• •Clinicial findings that in the opinion of the investigator would suggest condition(s) other than iMN as a major cause of severe proteinuria
• •Major surgery within 8 weeks prior to screening or planned surgery within 1 month following randomization
• •Blood pressure with systolic pressure above 160 mmHg and/or diastolic pressure above 100 mmHg despite antihypertensive treatment will in all cases be considered "uncontrolled"
• •Treated with systemic corticosteroids, or other immune suppressive, or immune modulating compounds within 4 weeks prior to screening and during the entire treatment period and until the final visit
• •Treated with rituximab within 12 months of screening
• •Evidence of active malignant disease
• •Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids
• •Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disease
• •Pregnant women or nursing mothers
• •History of alcohol, drug, or chemical abuse within the 6 months prior to screening
• •Any condition that in the view of the investigator would suggest that the patient is unable to comply with study protocol and procedures
• •Only Sweden:
• •Females of child-bearing potential.